Table 2.
Univariate and multivariate analyses of CSS in ESCC patients
| CSS (%) | Chi-square | P-value | HR (95% CI) | P-value | |
|---|---|---|---|---|---|
| Age (years) | 0.005 | 0.940 | – | – | |
| ≤60 | 33.5 | ||||
| >60 | 35.6 | ||||
| Sex | 0.001 | 0.980 | – | – | |
| Female | 35.3 | ||||
| Male | 34.4 | ||||
| Tumor length (cm) | 17.494 | <0.001 | 0.219 | ||
| ≤3 | 52.6 | 1.000 | |||
| >3 | 28.1 | 1.294 (0.858–1.952) | |||
| Tumor location | 0.548 | 0.459 | – | – | |
| Upper/middle | 37.1 | ||||
| Lower | 31.3 | ||||
| Differentiation | 2.781 | 0.095 | – | – | |
| Well/moderate | 35.8 | ||||
| Poor | 29.5 | ||||
| Vessel involvement | 8.543 | 0.003 | 0.395 | ||
| Negative | 37.4 | 1.000 | |||
| Positive | 19.1 | 1.174 (0.811–1.701) | |||
| Depth invasion | 24.961 | <0.001 | 0.036 | ||
| T1-2 | 56.5 | 1.000 | |||
| T3-4a | 24.4 | 1.527 (1.027–2.271) | |||
| Nodal metastasis | 54.063 | <0.001 | <0.001 | ||
| Negative | 53.0 | 1.000 | |||
| Positive | 15.3 | 2.101 (1.507–2.930) | |||
| Adjuvant therapy | 0.100 | 0.752 | – | – | |
| No | 36.7 | ||||
| Yes | 29.9 | ||||
| Alb (g/dL) | 23.484 | <0.001 | 0.160 | ||
| >3.5 | 40.4 | 1.000 | |||
| ≤3.5 | 15.7 | 1.285 (0.905–1.824) | |||
| BMI (kg/m2) | 10.370 | 0.001 | 0.741 | ||
| >18.5 | 40.4 | 1.000 | |||
| ≤18.5 | 24.5 | 1.060 (0.752–1.494) | |||
| NLR | 11.407 | 0.001 | 0.096 | ||
| <5 | 38.2 | 1.000 | |||
| ≥5 | 10.3 | 1.436 (0.938–2.198) | |||
| ALI | 19.847 | <0.001 | 0.024 | ||
| ≥18 | 43.4 | 1.000 | |||
| <18 | 21.7 | 1.433 (1.048–1.959) |
Note: Statistically significant P-values are shown in bold.
Abbreviations: CSS, cancer-specific survival; ESCC, esophageal squamous cell carcinoma; NLR, neutrophil to lymphocyte ratio; Alb, serum albumin; BMI, body mass index; ALI, advanced lung cancer inflammation index; CI, confidence interval; HR, hazard ratio.